Lemaitre Vascular Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $1.84B
  • PE 42
  • Debt $167.77M
  • Cash $25.61M
  • EV $1.98B
  • FCF $37.16M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$44.04M
EBIT$56.88M
ROE13%
ROA10%
FCF$37.16M
Equity$337.29M
Growth Stability94%
PE41.81
PEG2.65
PB5.46
P/FCF49.54
P/S8.37
Price/Cash0.01
Debt/Equity0.5
Debt/FCF4.51
Net Margins20%
Gross Margins69%
Op. Margins26%
Earnings CAGR13%
Sales Growth YoY14%
Sales Growth QoQ2%
Sales CAGR12%
FCF CAGR12%
Equity CAGR19%
Earnings Stability0.75
Earnings Growth YoY32%
Earnings Growth QoQ0%
Earnings CAGR 5Y16%
Sales CAGR 5Y14%
FCF CAGR 5Y8%
Equity CAGR 5Y19%
Earnings CAGR 3Y14%
Sales CAGR 3Y14%
FCF CAGR 3Y14%
Equity CAGR 3Y11%
Market Cap$1.84B
Revenue$219.86M
Dividend Yield1%
Payout Ratio33%
Assets$551.82M
Total Debt$167.77M
Cash$25.61M
Shares Outstanding22.45M
EV1.98B
Earnings Score91%
Moat Score93%
Safety Score87%
Final Score90%
Working Capital371.59M
Current Ratio13.14
Gross Profit$150.90M
Shares Growth 3y1%
Equity Growth QoQ2%
Equity Growth YoY13%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

SEC Filings

Direct access to Lemaitre Vascular Inc (LMAT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Lemaitre Vascular Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Lemaitre Vascular Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 13%
Stability 75%
loading chart...

Lemaitre Vascular Inc Discounted Cash Flow

Fully customizable DCF calculator online for Lemaitre Vascular Inc.

= $868M
012345678910TV
fcf$37M$42M$47M$52M$59M$66M$74M$83M$93M$105M$118M$1.2B
DCF$38M$39M$39M$40M$41M$42M$43M$44M$44M$45M$453M
Value$868M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins10%12%17%22%15%16%17%13%16%20%20%
ROA-16%17%19%12%11%12%9%11%10%10%
ROE-12%16%18%12%12%11%8%10%13%13%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF----01.120-04.514.51
Debt over Equity----00.210-00.50.5
Growth Stability---100%100%100%100%94%100%100%94%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-14%13%5%11%10%19%5%20%14%14%
Earnings YoY growth-37%62%34%-22%18%27%-23%46%46%16%
Equity YoY growth-12%25%19%14%16%47%6%11%13%19%
FCF YoY growth-53%17%0%-37%205%-5%-27%33%26%8%